Decibel Therapeutics
Biotechnology ResearchView the employees at
Decibel Therapeutics-
Kevin Lebo Director-level Principal Scientist and Head of Vectorology at Decibel Therapeutics
-
South Weymouth, Massachusetts, United States
-
Top 5%
Madeline Barnes Research Associate II at Decibel Therapeutics-
Greater Boston
-
Rising Star
-
Boston, Massachusetts, United States
-
Top 10%
Elaine Kernbauer Vice President, Clinical Development Operations-
Rising Star
Christine Kanalis Head of Clinical Data Analytics and Operations-
Fredericktown, Pennsylvania, United States
-
Rising Star
Overview
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of building a world of connection for people with hearing and balance disorders. Guidelines: https://bit.ly/3IzmNvU
-